Media Room
First quarter 2026
Q1 2026 results were reviewed by management during a live audio webcast with the financial community on April 23, 2026. The presentation was followed by a Q&A session.
Press Releases
June 12, 2026
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
June 10, 2026
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
June 8, 2026
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
October 2025
Annual Report on Form 20-F
Annual Report on Form 20-F 2025
July 2025
Half-year Financial Reports
Half Year 2025 Financial Report
July 2025
Half-year Financial Reports
Half year 2025 financial report XBRL package
September 2024
Annual Report on Form 20-F
Annual Report on Form 20-F 2024